Claritas HealthTech has unveiled ReDisys, an advanced artificial intelligence (AI) solution for detecting kidney cancer in computed tomography (CT) scans.
The London-based healthcare technology company specialises in medical image enhancement and AI-driven diagnostic tools.
ReDisys is a computer-aided detection software designed to support clinicians by identifying tumours and other abnormalities in kidney CT images.
Claritas HealthTech said that it is working closely with key industry stakeholders throughout the clinical evaluation and regulatory clearance processes.
ReDisys aims to offer a highly accurate AI tool that enhances cancer detection for clinicians.
By improving detection precision, the AI tool aims to minimise unnecessary biopsies, ultimately leading to better patient experiences and outcomes.
Claritas HealthTech chief surgical officer Rajesh Nair said: “With ReDisys, we continue our work in R&D to bring to market solutions that improve kidney cancer diagnostics.
“In a disease where there are challenges in differentiating cancerous change from non-cancer, ReDisys looks to aid the clinician when faced with these variations in imaging characteristics of renal conditions.
“With this tool we aim to assist clinicians in their workflow when managing renal tumours, fast-tracking intervention for image-predicted aggressive tumours or safely facilitating surveillance of the non-aggressive kidney cancers. ReDisys enables personalised kidney cancer care.”
The healthcare technology firm focuses on research and development in image enhancement, machine vision, and AI, particularly in medical image processing and AI-assisted diagnostics.
Claritas HealthTech uses image enhancement and AI technologies to empower doctors and physicians to make more accurate diagnoses and improve patient outcomes.
The latest announcement comes after Claritas HealthTech revealed its plans to spin off its nuclear medicine division into a separate company, Claritas NucMed Technologies.
Claritas NucMed will concentrate on the global commercialisation, delivery, and deployment of its suite of software solutions for PET and SPECT nuclear medicine imaging.
In December 2023, Intelligent Scopes, a subsidiary of Claritas HealthTech, signed a new know-how agreement with Mayo Clinic to develop AI solutions for enhancing surgical and endoscopic imaging in urology.
